Senzime (SEZI.ST) Stock Analysis & AI Equity Report
Senzime (SEZI.ST) overview
Senzime (SEZI.ST) stock analysis and AI equity research. For the latest completed financial year, 2025, Senzime reported revenue of SEK 104m and operating profit of SEK -121m; the year-end share price was 5.40 SEK and market capitalisation was SEK 794m. Senzime is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Senzime's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2026-07-27. Data will be refreshed during report generation.
About Senzime
Senzime AB is a medical technology company that develops and sells precision-based patient monitoring systems for use during and after surgery. Its main products are TetraGraph for neuromuscular monitoring and ExSpiron for respiratory monitoring. The company also offers software and related sensors, with sales through direct channels and distributors.
Generate the Senzime report
Senzime is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Senzime and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.